Company / Free Cash Flow
Corvus Pharmaceuticals, Inc. Free Cash Flow History
FY2015-FY2023 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Free Cash Flow
-$24.0M
FY2023
5-year range
-$36.7M / -$24.0M
FY2019-FY2023
Trend
+12.2%
vs FY2022
Sector context
#71 of 192
Health Care
What the data says
At -$24M, Corvus Pharmaceuticals, Inc.'s free cash flow ranks #71 of 192 in the Health Care sector. Free Cash Flow has fluctuated over the past 9 years, ranging from -$46M in FY2017 to -$13M in FY2015.
Based on SEC 10-K filings.
-$24M in FY2023.
Improved from -$37M to -$24M over the past 2 years.
Health Care sector context is included.
Free Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#71 of 192 in Health CareTop 37% of 192This company -$24.0M Sector average $474.2M
▼
-105.1% below sector average
Key checks
Key Insights
- In FY2023, free cash flow increased 12.2% year-over-year.
- Ranks #71 out of 192 companies in the Health Care sector.
- Peak free cash flow was recorded in FY2015.
- Lowest free cash flow in the period was in FY2017.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -0.67 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Free Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | - | - |
| FY2023 | -$24.0M | +12.2% |
| FY2022 | -$27.3M | +25.7% |
| FY2021 | -$36.7M | -5.4% |
| FY2020 | -$34.9M | +6.7% |
| FY2019 | -$37.3M | +9.7% |
| FY2018 | -$41.3M | +11.0% |
| FY2017 | -$46.5M | -54.6% |
| FY2016 | -$30.1M | -129.9% |
| FY2015 | -$13.1M | - |
As of FY2023 · SEC 10-K · Updated Feb 28, 2026